6/21/2023 0 Comments Generic face for facebook profile![]() “Our outlook for FY2023 reflects the challenges of anticipated generic impact and lower coronavirus vaccine contributions, but we still anticipate delivering core operating profit above 1 trillion yen. As a result, we are forecasting a dividend increase for the first time in 15 years, from 180 yen to 188 yen per share. “Strong financial discipline and free cash flow have enabled us to deleverage rapidly while investing in growth. Our topline and profit performance was driven by our Growth & Launch Products, which grew 19% at constant exchange rate. ![]() “I’m pleased to report that Takeda delivered or exceeded management guidance in FY2022 and booked a record core operating profit of almost 1.2 trillion yen. Takeda chief financial officer, Costa Saroukos, commented: We will continue to strengthen our long-term competitiveness through investments in R&D and data and technology, as we deliver on our purpose to bring better health for people and a brighter future for the world.” “While we expect to face temporary headwinds in FY2023 from generic entrants and lower demand for coronavirus vaccines, we are confident that strong momentum in our Growth & Launch Products will drive a return to growth in the near-term. We have adopted a progressive dividend policy of increasing or maintaining the dividend each year, and in FY2023 we intend to raise the dividend to underscore confidence in our future growth profile. ![]() “We have updated our capital allocation policy as a reflection of our deleveraging progress and our new phase of investment for growth and shareholder returns. Important pipeline milestones included the first approvals for our dengue vaccine QDENGA ®, positive late-stage readouts for TAK-755 and fazirsiran, and the acquisition of TAK-279 for immune-mediated diseases. “FY2022 was another strong year for Takeda, reflecting successful execution against our business strategy and advancements in our innovative pipeline-enabling us to deliver truly transformative treatments to patients. Takeda president and chief executive officer, Christophe Weber, commented: Takeda ( TOKYO:4502/NYSE:TAK) today announced strong financial results for fiscal year 2022 (period ended March 31, 2023), delivering or exceeding management guidance, driven by the performance of its Growth & Launch Products. Planned Dividend Increase to 188 Yen per Share in FY2023.FY2023 Core Operating Profit Expected to Remain >1 Trillion Yen Despite Impact of Loss of Exclusivity and Lower Expectations for Coronavirus Vaccines.Achieved Core Operating Profit of 1,188.4 Billion Yen – Exceeding 1 Trillion Yen for the First Tim e in the Company’s History.Full Year Reported Revenue Growth of + 12.8% Core Revenue Growth of +3.5% at Constant Exchange Rate Driven by Growth & Launch Products Reported EPS Growth of +38.8%.
0 Comments
Leave a Reply. |